Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.72 USD | -6.93% | -4.41% | +357.14% |
05-30 | FDA Grants Candel Therapeutics' CAN-3110 Orphan Drug Designation to Treat Recurrent High-Grade Glioma | MT |
05-30 | Candel Therapeutics Gets FDA's Orphan-Drug Status for Glioma Treatment | DJ |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+357.14% | 215M | |
+34.01% | 52.85B | |
-8.02% | 38.87B | |
+34.86% | 38.24B | |
-11.12% | 26.79B | |
+12.56% | 26.16B | |
-19.62% | 19.9B | |
+39.18% | 13.18B | |
+31.47% | 12.24B | |
-3.40% | 11.79B |
- Stock Market
- Equities
- CADL Stock
- News Candel Therapeutics, Inc.
- Transcript : Candel Therapeutics, Inc. Presents at B. Riley Securities' 3rd Annual Oncology Conference, Jan-19-2023 11